Clinical Trials
31 trialsTesting the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
National Cancer Institute (NCI)
Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
ANVIL
National Cancer Institute (NCI)
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
National Cancer Institute (NCI)
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
National Cancer Institute (NCI)
LOOP
AstraZeneca
SAVED LUNG
Centre hospitalier de l'Université de Montréal (CHUM)
TEMPUS Small Cell Lung Cancer OBSERVATIONAL STUDY (Sculptor)
Tempus AI
GIVEN
Guangdong Provincial People's Hospital
GEMINI-NSCLC: NSCLC Biomarker Study
Tempus AI
Generation of Reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines
The First Affiliated Hospital of Soochow University
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
EDUR-BRA
AstraZeneca
Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients
Geneplus-Beijing Co. Ltd.
Observation on the Frailty Status of Lung Cancer Patients
Peking University Third Hospital
Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy
Sun Yat-sen University
NAT-LungMate
Shanghai Pulmonary Hospital, Shanghai, China
PADMA
Insight Molecular Diagnostics
CheckMate 9TN
Bristol-Myers Squibb
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer
Assiut University
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
Xiangya Hospital of Central South University
PSM
Oslo University Hospital
IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer
Hospices Civils de Lyon
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
CBP-Aggrav
University Hospital, Grenoble
Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
University of Wisconsin, Madison
Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain Metastasis
Samsung Medical Center